

=> d his

(FILE 'HOME' ENTERED AT 10:57:36 ON 20 NOV 2007)

FILE 'REGISTRY' ENTERED AT 10:57:44 ON 20 NOV 2007

L1 SCREEN 1839
L2 SCREEN 1840
L3 STRUCTURE UPLOADED
L4 835823 S SC4/ES
L5 5 S (L3 NOT L2) SAM SUB=L4
L6 159 S (L3 NOT L2) SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 10:59:53 ON 20 NOV 2007


L7 21 S L6
L8 2 S US200!-537697/APPS
L9 1 S L7 AND L8
L10 20 S L7 NOT L8

FILE 'REGISTRY' ENTERED AT 11:00:22 ON 20 NOV 2007

=> d l3

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 19 bib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:515662 CAPLUS
DN 141:47386
TI Ureidothiophene compound NF- κ B inhibitor for therapeutic use
IN Callahan, James Frances; Li, Yue Hu
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053087	A2	20040624	WO 2003-US38970	20031205
	WO 2004053087	A3	20040910		
	W:	AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, VN, YU, ZA			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003300832	A1	20040630	AU 2003-300832	20031205
	EP 1569924	A2	20050907	EP 2003-812858	20031205
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006510676	T	20060330	JP 2004-559435	20031205
	US 2006116419	A1	20060601	US 2005-537697	20050606 <--
PRAI	US 2002-431496P	P	20021206		
	WO 2003-US38970	W	20031205		

AB The invention provides 5-(4-fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide (preparation described) and methods for treating diseases related to the inhibition of IKK- β phosphorylation of I κ .


=> d 110 tot bib abs hitstr

ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 2007:1060852 CAPLUS Full-text
 DN 147:378396
 TI nf-kb activation inhibitors for treating muscular wasting diseases
 IN Guttridge Denis C., Baldwin, Albert S.
 PA Therapeutics, Inc., USA
 SO PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007106884	A2	20070920	WO 2007-US64057	20070315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2007225315	A1	20070927	US 2007-686623	20070315
PRAI US 2006-782427P	P	20060315		
AB	Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment a nuclear factor kappa B (NF-κB) activation inhibitor capable of blocking the activation of NF-κB. Administration of peptides comprised of a Nuclear Factor Essential (NEMO) binding domain to a mouse model of Duchenne muscular dystrophy significantly increased diaphragm contractions.			
IT 354810-86-9	507475-17-4			
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
(nf-kb activation inhibitors for treating muscular wasting diseases)				
RN 354810-86-9	CAPLUS			
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)				



RN 507475-17-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 2007:279958 CAPLUS Full-text
 DN 146:493299
 TI Inhibition of Aβ production by NF-κB inhibitors
 AU Paris, Daniel; Patel, Nikunj; Quadros, Amita; Linan, Monica; Bakshi, Pancham; Ait-Ghezala, Ghania; Mullan, Michael
 CS Roskamp Institute, Sarasota, FL, 34243, USA
 SO Neuroscience Letters 407(1), 415(1), 11-16
 CODEN: NELED5; ISSN: 0304-3940
 PB Elsevier Ltd.
 DT Journal
 LA English
 AB The transcription factor nuclear factor κB (NF-κB) is widely expressed in the nervous system and increased NF-κB immunoreactivity has been observed in Alzheimer's disease (AD) brains in the nuclei of neurons within the vicinity of diffuse β-amyloid plaques. β-Amyloid (Aβ) peptides are the main constituent of senile plaques and are known to stimulate NF-κB activity. In the present study, we investigated the effect of various NF-κB inhibitors on the production of Aβ1-40, Aβ1-42, secreted APP (sAPPβ) and APP C-terminal fragments (APP-CTF) using CHO cells overexpressing the β-amyloid precursor protein (APP). Our data show that NF-κB inhibitors decrease both Aβ1-40 and Aβ1-42 production. In addition, we show that some NF-κB inhibitors decrease sAPPβ and APP-CTFβ suggesting that they reduce the β-secretase cleavage of APP. Altogether our data suggest that NF-κB inhibitors may be of therapeutic importance for the treatment of AD pathol. not only by blocking inflammatory processes but also by directly inhibiting the production of Aβ peptides.
 IT 507475-17-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of Aβ production by NF-κB inhibitors)
 RN 507475-17-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 2007:76699 CAPLUS Full-text
 DN 146:115045
 TI Treating type 2 diabetes or metabolic syndrome with an interleukin 1β inhibitor or an interleukin 1β synthesis or release inhibitor
 PA Novo Nordisk A/S, Den.
 SO Dan. Pat. Appl., 16pp.
 CODEN: DAXXBG
 DT Patent
 LA English
 FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DK 2006000313	A	20060313	DK 2006-313	20060303
PRAI DK 2006-313		20060303		
AB	The invention describes a method for treating type 2 diabetes or metabolic syndrome with a compound that inhibits (a) 1L-1β, (b) the synthesis of 1L-1β, or (c) the release of 1L-1β.			
IT 354810-80-3	354810-82-6	354810-86-9		
354810-80-1	354810-85-0	354811-01-1		
354811-04-4	354811-06-6	354811-07-7		
354811-08-8	354811-09-9	354811-10-2		
354811-14-6	354811-15-7	354811-19-1		
354811-27-1	354811-28-2	354811-29-3		
354811-30-6	354811-31-7	354811-32-8		
354811-33-5	354811-34-0	354811-35-1		
354811-36-2	354811-37-3	354811-38-4		
354811-39-5	354811-40-8	354811-41-9		
354811-42-0	354811-48-6	354811-49-7		
354811-50-0	354811-52-2	354811-54-4		
354811-56-6	354811-58-8	354811-59-9		
354811-60-2	354811-66-8	354811-67-5		
354811-68-0	354811-82-8	354811-03-0		
518475-53-3				
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
(interleukin 1β inhibitor or interleukin 1β synthesis or release inhibitor for treatment of type 2 diabetes or metabolic syndrome)				
RN 354810-80-3	CAPLUS			
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)				




RN 354810-83-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)


INDEX NAME)




RN 354810-86-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




RN 354810-88-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




RN 354810-95-0 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 354811-01-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)




RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 354811-07-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-(dimethylamino)ethoxy]phenyl- (CA INDEX NAME)




RN 354811-08-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(2-(dimethylamino)ethoxy)phenyl]- (CA INDEX NAME)




RN 354811-19-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-(dimethylamino)propoxy]phenyl- (CA INDEX NAME)




RN 354811-27-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-(3-(dimethylamino)propoxy)phenyl]- (CA INDEX NAME)




RN 354811-28-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-29-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)




RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




RN 354811-14-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(3-(dimethylamino)propoxy)phenyl]- (CA INDEX NAME)




RN 354811-15-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-(2-(dimethylamino)ethoxy)phenyl]- (CA INDEX NAME)




RN 354811-30-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (CA INDEX NAME)




RN 354811-31-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-32-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-33-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-34-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)





RN 354811-35-1 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-36-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-41-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 354811-42-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 354811-48-6 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-49-7 CAPLUS


RN 354811-37-3 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-38-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-39-5 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-40-8 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-50-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-52-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (CA INDEX NAME)




RN 354811-54-4 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)




RN 354811-56-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (CA INDEX NAME)





RN 354811-58-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)- (CA INDEX NAME)




RN 354811-59-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-60-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)- (CA INDEX NAME)



RN 354811-83-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-{2-(diethylamino)ethoxy}phenyl]- (CA INDEX NAME)



RN 918475-53-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-{1,1-dimethylethyl}phenyl]- (CA INDEX NAME)



ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:56134 CAPLUS Full-text

DN 147:163639

TI Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model

AU Birrell, M. A.; McCluskie, K.; Hardaker, E.; Knowles, R.; Belvisi, M. G.

CS Respiratory Pharmacology, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, London, UK


SO European Respiratory Journal (2006), 28(6), 1236-1244
CODEN: ERJODI; ISSN: 0903-1936

PB European Respiratory Society


DT Journal
LA English

AB There is a great deal of interest in developing less invasive markers for monitoring airway inflammation and the effect of possible novel anti-inflammatory therapies that may take time to impact on disease pathol. Exhaled nitric oxide (eNO) has been shown to be a reproducible, noninvasive indicator of the inflammatory status of the airway in the clinic. The aim of the present study was to determine the usefulness of measuring eNO as a marker


RN 354811-66-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



RN 354811-68-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 354811-82-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-{2-(dimethylamino)ethoxy}phenyl]- (CA INDEX NAME)




of the anti-inflammatory impact of glucocorticoid and an inhibitor of κ B kinase-2 (IKK-2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), in a pre-clin. model of airway inflammation. Rats were given vehicle, budesonide or TPCA-1 prior to exposure to lipopolysaccharide, previously shown to induce an increase in eNO and airway neutrophilia/eosinophilia. Comparison of the effect of the two compds. on inflammatory components demonstrated a significant correlation between the impact on eNO and inflammatory cell burden in the airway. The current study demonstrates the usefulness of profiling potential disease-modifying therapies on exhaled nitric oxide levels and the way in which an effect on this noninvasive biomarker relates to effects on pathol. parameters such as lung cellularity. Information from studies such as the current one would suggest that the measurement of exhaled nitric oxide has potential for monitoring inflammatory status in lung tissue.

IT 507475-17-4, TPCA-1

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exhaled nitric oxide as noninvasive biomarker of airway inflammation in a rat model)

RN 507475-17-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE/CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1157366 CAPLUS Full-text

DN 145:465677

TI BAFF and APRIL neutralization-based methods for treating disease by regulating chronic lymphocytic leukemia (CLL) cell survival

IN Kipps, Thomas J.; Endo, Tomoyuki; Nishio, Mitsufumi

PA The Regents of the University of California, USA

SO PCT Int. Appl., 52pp.

CODEN: PIXXD2

DT Patent


LA English

FAN/CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116366	A2	20061102	WO 2006-US15572	20060424
WO 2006116366	A3	20070405		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

VN, YU, ZA, ZM, ZW
 RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 PRAI US 2005-674239P P 20050422
 AB The invention discloses methods for regulating apoptosis in a cell comprising contacting the cell with an agent capable of neutralizing BAPF or APRIL. The invention also discloses a method for treating leukemia. The invention further discloses a method for detecting inhibitors of CLL.
 IT 507475-17-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (BAPF and APRIL neutralization-based methods for treating disease by regulating chronic lymphocytic leukemia cell survival)
 RN 507475-17-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2006:551763 CAPLUS Full-text
 DN 145:180624
 TI IκB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic
 AU Birrell, Mark A.; Wong, Sissie; Hardaker, Elizabeth L.; Catley, Matthew C.; McCluskie, Kerry; Collins, Michael; Haj-Yahia, Saleem; Belvisi, Maria G.
 CS Respiratory Pharmacology Group, Airway Diseases Department, Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, UK
 SO Molecular Pharmacology (2006), 69(6), 1791-1800
 CODEN: MOPMA3; ISSN: 0026-895X
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 AB Nuclear factor κB (NF-κB) is a transcription factor believed to be central in the expression of numerous inflammatory genes and the pathogenesis of many respiratory diseases. We have previously demonstrated increased NF-κB pathway activation in a steroid-sensitive animal model of lipopolysaccharide (LPS)-driven airway inflammation. It is noteworthy that this phenomenon was not observed in a steroid-insensitive model of elastase-induced inflammation in the rat. The aim of this study was to gather further evidence to suggest that these similar profiles of neutrophilic inflammation can be NF-κB-dependent or -independent by determining the impact of an IκB kinase-2 (IKK-2) inhibitor, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1). In the LPS model, TPCA-1 blocked the increase in NF-κB DNA binding, a marker


of NF-κB pathway activation. This inhibition was associated with a reduction in inflammatory mediator release [tumor necrosis factor α (TNF-α)/interleukin-1β (IL-1β)/matrix metalloproteinase-9 (MMP-9)] and lung inflammatory cell burden (neutrophilia/eosinophilia). These data were paralleled with a steroid and in human cell based assays. In the elastase-driven inflammation model, in which our group has previously failed to measure an increase in NF-κB DNA binding, neither TPCA-1 nor the steroid, affected mediator release (IL-1β/MMP-9) or cellular burden (neutrophilia/lymphomononuclear cells). This is the first study to examine the effect of an IKK-2 inhibitor in well validated models that mimic aspects of the inflammatory lesion evident in diseases such as COPD. In conclusion, we have demonstrated that animal models with similar profiles of airway inflammation can be IKK-2 inhibitor/steroid-sensitive or -insensitive. If both profiles of inflammation exist in the clinic, then this finding is extremely exciting and may lead to greater understanding of disease pathol. and the discovery of novel anti-inflammatory targets.
 IT 507475-17-4, TPCA 1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (IκB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic)
 RN 507475-17-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2006:357148 CAPLUS Full-text
 DN 145:39831
 TI Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies
 AU Morwick, Tina; Berry, Angela; Brickwood, Janice; Cardozo, Mario; Catron, Katrina; DeTurri, Molly; Emeigh, Jonathan; Homon, Carol; Hrapchak, Matt; Jacober, Stephen; Jakes, Scott; Kaplita, Paul; Kelly, Terence A.; Kulazek, John; Luzzi, Michel; Magolda, Ronald; Mao, Can; Marshall, Daniel; McNeill, Daniel; Prokopowicz, Anthony, III; Sarko, Christopher; Scouten, Erika; Sledziona, Cynthia; Sun, Sanxing; Watrous, Jane; Wu, Jiang Ping; Cywin, Charles L.
 CS Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 06801-0368, USA
 SO Journal of Medicinal Chemistry (2006), 49(10), 2898-2908
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 145:39831

AB High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large nos. of active compds. are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IκB kinase-β (IKKβ), a key regulatory enzyme in the nuclear factor-κB (NF-κB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering addnl. opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.
 IT 718620-78-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (thienopyridine class of inhibitors of IκB kinase-β: hit-to-lead strategies)
 RN 718620-78-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(methilamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)




IT 354810-80-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (thienopyridine class of inhibitors of IκB kinase-β: hit-to-lead strategies)
 RN 354810-80-3 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2005:777848 CAPLUS Full-text
 DN 145:262418
 TI A Critical Assessment of Docking Programs and Scoring Functions

AU Warren, Gregory L.; Andrews, C. Webster; Capelli, Anna-Maria; Clarke, Brian; Lalonde, Judith; Lambert, Millard H.; Lindvall, Mika; Nevins, Nyesa; Semus, Simon F.; Senger, Stefan; Tedesco, Giovanna; Wall, Ian D.; Woolven, James M.; Peishoff, Catherine E.; Head, Martha S.
 CS GlaxoSmithKline Pharmaceuticals, Collegeville, PA, 19426, USA
 SO Journal of Medicinal Chemistry (2006), 49(20), 5912-5931
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Docking is a computational technique that samples conformations of small mole. in protein binding sites; scoring functions are used to assess which of these conformations best complements the protein binding site. An evaluation of 10 docking programs and 37 scoring functions was conducted against eight proteins of seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization. All of the docking programs were able to generate ligand conformations similar to crystallog. determined protein/ligand complex structures for at least one of the targets. However, scoring functions were less successful at distinguishing the crystallog. conformation from the set of docked poses. Docking programs identified active compds. from a pharmaceutically relevant pool of decoy compds.; however, no single program performed well for all of the targets. For prediction of compound affinity, none of the docking programs or scoring functions made a useful prediction of ligand binding affinity.
 IT 507475-23-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (critical assessment of docking programs and scoring functions)
 RN 507475-23-2 CAPLUS
 CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-N-methyl-2-[[[(methilamino)carbonyl]amino]- (CA INDEX NAME)





RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2005:638873 CAPLUS Full-text
 DN 143:153276
 TI Preparation of substituted heterocycles, particularly ureidothiophenes, as CHK1 kinase inhibitors for treating neoplasms
 IN Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janetka, James; Lyne, Paul; Su, Mei; Toader, Dorin; Yu, Dingwei; Yu, Yan
 SO AstraZeneca AB, Swed.; AstraZeneca UK Limited
 PA FCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CMT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005066163	A2	20050721	WO 2004-GB5400	20041224
WO 2005066163	A3	20050901		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312193	A1	20050721	AU 2004-312193	20041224
CA 2552050	A1	20050721	CA 2004-2552050	20041224
EP 1732920	A2	20061220	EP 2004-806196	20041224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1922172	A	20070228	CN 2004-80042170	20041224
BR 2004018351	A	20070508	BR 2004-18351	20041224
JP 2007517843	T	20070705	JP 2006-548370	20041224
US 2007010556	A1	20070111	US 2006-596930	20060629
NO 2006003449	A	20060727	NO 2006-3449	20060726
IN 2006MN00910	A	20070413	IN 2006-MN910	20060731
PRAI US 2004-534310P	P	20040405		
US 2004-553305P	P	20040415		
WO 2004-GB5400	W	20040724		
OS MARPAT 143:153276				
GI				




AB Title compds. I (wherein X = NH, S, O; Y = CH, N; R1 = CN, (un)substituted alk(en)yl, alkoxy, aryl, etc.; R2, R3 = independently CONH2 and derivs., SO2NH2 and derivs., NHCONHR4; R4 = H, OH, benzyl, etc.; and their pharmaceutically acceptable salts; provided that when X = S; Y = CH; R2 = CONH2 and derivs.; and R3 = NHCONHR4; then R1 cannot be hydroxyphenyl or alkoxyphenyl; with the exception of certain compds.) were prepared as




RN 860353-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-phenyl- (CA INDEX NAME)



RN 860353-74-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(dimethylamino)ethyl]-5-phenyl- (CA INDEX NAME)



RN 860353-89-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-phenyl- (CA INDEX NAME)




checkpoint kinase 1 inhibitors for treating cancer. For example, a 7-step synthesis of ureidothiophene salt II·HCl, starting from phenylacetaldehyde and cyanomethyl acetate, is given. I had IC50 or EC50 ≤ 100 μM in one or both, checkpoint kinase 1 and abrogation assays.

IT 860351-93-5P, (R)-2-Amino-3-[[[(5-phenyl-3-ureidothien-2-yl)carbonyl]amino]propionic acid methyl ester 860351-94-5P, 5-Phenyl-3-ureidothiophene-2-carboxylic acid ((2R)-2-amino-3-hydroxypropyl)amide 860351-95-7P, 5-Phenyl-3-ureidothiophene-2-carboxylic acid ((2S)-2-amino-3-hydroxypropyl)amide 860351-96-7P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-aminoethyl)amide 860353-74-8P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-dimethylaminoethyl)amide 860353-89-5P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-hydroxyethyl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of ureidothiophenes as CHK1 kinase inhibitors for treating neoplasm)


RN 860351-93-5 CAPLUS
CN D-Alanine, 3-[[[(3-[(aminocarbonyl)amino]-5-phenyl-2-thienyl)carbonyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 860351-94-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-[(2R)-2-amino-3-hydroxypropyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 860351-95-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-[(2S)-2-amino-3-hydroxypropyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.


AN 2005:158658 CAPLUS Full-text
DN 142:261391
TI Preparation of thiophene compounds as CHK1 inhibitors
IN Ashwell, Susan; Gero, Thomas; Ioannidis, Stophanos; Janetka, James; Lyne, Paul; Oza, Vibha; Springer, Stephanie; Su, Mei; Yu, Dingwei
PA AstraZeneca AB, Sweden; AstraZeneca UK Limited
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CMT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005016909	A1	20050224	WO 2004-GB3473	20040812
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004265140	A1	20050224	AU 2004-265140	20040812
CA 2535652	A1	20050224	CA 2004-2535652	20040812
EP 1660474	A1	20060531	EP 2004-768043	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004013585	A	20061017	BR 2004-13585	20040812
CN 1867557	A	20061122	CN 2004-80030364	20040812
JP 2007502308	T	20070208	JP 2006-523673	20040812
IN 2006DN00703	A	20070824	IN 2006-DN703	20060213
NO 2006000718	A	20060301	NO 2006-718	20060214
US 2006281666	A1	20060214	US 2006-568380	20060214
MX 2006PA01775	A	20060517	MX 2006-PA1775	20060215
PRAI US 2001-495580P	P	20010815		
US 2004-576416P	P	20040528		
WO 2004-GB3473	W	20040812		
OS CASREACT 142:261391; MARPAT 142:261391				
GI				




RN 728947-84-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-91-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(5-cyanopentyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728947-93-1 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-methylpropyl)amino]methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 728947-92-0

CMF C17 H22 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 728947-97-5 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-hydroxyethyl)amino]methyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 728947-96-4

CMF C15 H18 N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 728947-98-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-methoxy-2-methylpropyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-03-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(ethyl(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-04-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(2-methoxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-06-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(2-cyanoethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-07-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(2-methoxyethyl)(1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-12-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-13-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-17-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[(2-methoxy-2-methylpropyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-18-3 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(3-methoxypropyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 728948-19-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(diethylamino)methyl]phenyl]- (CA INDEX NAME)




RN 728948-20-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-cyanoethyl)methyl]phenyl]- (CA INDEX NAME)




RN 728948-22-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-hydroxyethyl)methyl]phenyl]- (CA INDEX NAME)



RN 728948-24-1 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[bis(2-hydroxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)




IT 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide 728948-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiophenecarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)


RN 494773-25-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



RN 728948-31-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



ANSWER 13 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

2004:362566 CAPLUS Full-text

ON 141:99000

TI Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

AU Baxter, Andrew; Brough, Steve; Cooper, Anne; Floettmann, Eike; Foster, Steve; Harding, Christine; Kettle, Jason; McInally, Tom; Martin, Craig; Mobbs, Michelle; Needham, Maurice; Newham, Pete; Paine, Stuart; St-Galley, Steve; Salter, Sylvia; Unitt, John; Xue, Yafeng

CS AstraZeneca R&D Charnwood, Loughborough, LE11 5RH, UK

SO Bioorganic & Medicinal Chemistry Letters 2004, 14(11), 2817-2822


CODEN: BMCLB8, ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

G1



AB A hit-to-lead optimization program was carried out on the thiophenecarboxamide high throughput screening hits 1 and 2 resulting in the discovery of the potent and orally bioavailable IKK-2 inhibitor (I).

IT 354810-83-6 354810-95-0 354811-01-1

354811-04-4 354811-06-6 354811-09-8


354811-10-2 718620-76-9 718620-77-0

718620-78-1 718620-79-2 718620-81-6

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)


RN 354810-83-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)




RN 354810-95-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 354811-01-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-04-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)



RN 354811-06-6 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)




10537697

41 of 87


RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)




RN 354811-10-2 CAPLUS
CN 2-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 718620-75-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-methyl-5-phenyl- (CA INDEX NAME)



RN 718620-77-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N,N-dimethyl-5-phenyl- (CA INDEX NAME)




RN 718620-78-1 CAPLUS


10537697

42 of 87


CN 2-Thiophenecarboxamide, 3-[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



RN 718620-79-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(ethylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)




RN 718620-81-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(dimethylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



IT 354810-80-3
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)

RN 354810-80-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




10537697

43 of 87

IT 354810-86-9
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)

RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE. CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2003.282559 CAPLUS Full-text

DN 138.304153

TI Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders

IN Parrish, Cynthia A.; Callahan, James F.; Li, Yue; Stavenger, Robert A.; Holt, Dennis A.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029241	A1	20030410	WO 2002-US31752	20021004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GR, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: CH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002340102	A1	20030414	AU 2002-340102	20021004
PRAI US 2001-326977P	P	20011004		
WO 2002-US31752	W	20021004		
OS MARPAT 138.304153				
GI				

10537697

44 of 87



AB Ureidothiophenes (shown as I; variables defined below; e.g. 5-(4-fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide) useful in the inhibition of angiogenesis and damage response kinases (no data) are provided. Although the methods of preparation are not claimed, 46 example preps. are included. For I: R1 = H, C1-2 alkyl, XH, XCH3, C1-2-alkyl-XH, C1-2 alkyl-XCH3, C(O)NH2, C(O)NHCH3, and C(O)-C1-2-alkyl; X = O, S, and NH; R2 = C(O)R5, CO2R5, C(O)NHR5, C(O)NHC(NH)R5, C(O)NHC(NH)NR5R6, C(O)NHC(O)R5, C(O)NHC(O)NR5R6, SO2R5, S(O)R5, SO3R5, and PO3R5R6. R3 is H or halogen; R4 is aryl or heteroaryl; addnl. details are given in the claims.

IT 105666-34-6P, 2-(3-Methylureido)-5-phenylthiophene-3-carboxylic acid amide 354811-10-2P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid amide 354811-09-9P, 5-(4-Trifluoromethylphenyl)-2-ureidothiophene-3-carboxylic acid amide 354811-07-6P, 5-(4-Chlorophenyl)-2-ureidothiophene-3-carboxylic acid amide 354812-11-6P, 5-(4-Methoxyphenyl)-2-ureidothiophene-3-carboxylic acid amide 412914-36-4P, 5-(3-Chlorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 412914-37-5P, 5-(4-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 412914-52-4P, 2-(3-Ethylureido)-5-phenylthiophene-3-carboxylic acid amide 412914-54-6P, 5-(2-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 412914-57-9P, 2-(3-Methylureido)-5-p-tolylthiophene-3-carboxylic acid amide 412914-58-0P, 5-(3-Chloro-4-fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-17-4P, 5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-20-9P, 5-p-Tolyl-2-ureidothiophene-3-carboxylic acid amide 507475-21-0P, 5-(4-Chlorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-23-2P, 5-(4-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methanide 507475-24-3P, 5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid methanide 507475-25-4P, 2-(3-Methylureido)-5-phenylthiophene-3-carboxylic acid methanide 507475-26-5P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid methanide 507475-29-8P, 5-(2-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-35-6P, 5-(4-Methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-37-8P, 5-(4-Cyanophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-38-9P, 5-(4-Dimethylaminophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-39-0P, 5-(4-Hydroxymethylphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-40-3P, 5-(3-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-41-4P, 5-(3-Aminophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-43-6P, 5-(4-Aminophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-44-7P, 5-(3-Hydroxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-46-9P, 5-(3-Acetylphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-50-5P, 2-(3-Methylureido)-5-(3-trifluoromethylphenyl)thiophene-3-carboxylic acid methanide 507475-51-6P, 5-(4-Methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methanide 507475-52-7P, 5-(4-Aminophenyl)-2-(3-


methylureido)thiophene-3-carboxylic acid methylamide 507475-53-8P,
 5-(4-Hydroxy-3-methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic
 acid methylamide 507475-54-2P, 5-(4-Hydroxymethylphenyl)-2-(3-
 methylureido)thiophene-3-carboxylic acid methylamide 507475-55-9P,
 5-(3,4-Dimethoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid
 methylamide 507475-56-1P, 5-(3-Fluorophenyl)-2-ureidothiophene-3-
 carboxylic acid amide 507475-57-2P, 5-(3-Cyanophenyl)-2-
 ureidothiophene-3-carboxylic acid amide 507475-58-3P,
 5-(4-Ethylphenyl)-2-ureidothiophene-3-carboxylic acid amide
 507475-59-4P, 5-(3-Methoxyphenyl)-2-ureidothiophene-3-carboxylic
 acid amide 507475-60-3P, 5-(3-Hydroxymethylphenyl)-2-
 ureidothiophene-3-carboxylic acid amide 507475-61-5P,
 5-(3,4-Dichlorophenyl)-2-ureidothiophene-3-carboxylic acid amide
 507475-62-5P, 5-(3-Trifluoromethylphenyl)-2-ureidothiophene-3-
 carboxylic acid amide 507475-63-6P, 5-(3,4-Difluorophenyl)-2-
 ureidothiophene-3-carboxylic acid amide 507475-64-1P,
 [5-Phenyl-3-(1-ureidomethanoyl)thiophen-2-yl]urea 507475-65-2P,
 1-Methyl-3-[5-phenyl-3-(1-ureidomethanoyl)thiophen-2-yl]urea
 507475-67-4P, (5-(4-Fluorophenyl)-3-(1-ureidomethanoyl)thiophen-2-
 yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of 2-ureidothiophenes as angiogenesis and Chk1
 kinase inhibitors for treating various forms of cancer and
 hyperproliferative disorders)


RN 106666-34-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-phenyl]- (CA INDEX NAME)




RN 354811-10-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-phenyl]- (CA INDEX NAME)




RN 354811-59-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-67-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




RN 354811-68-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 354812-11-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 412914-36-4 CAPLUS

CN 3-Thiophenecarboxamide, 5-(3-chlorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 412914-37-5 CAPLUS

CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 412914-52-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(ethylamino)carbonyl]amino]-5-phenyl]- (CA INDEX NAME)




RN 412914-54-6 CAPLUS

CN 3-Thiophenecarboxamide, 5-(2-fluorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 412914-57-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-(4-methylphenyl)- (CA INDEX NAME)




RN 412914-58-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 507475-17-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




RN 507475-20-9 CAPLUS


CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(4-methylphenyl)- (CA INDEX NAME)




RN 507475-21-0 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-chlorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-23-2 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-24-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 507475-25-4 CAPLUS
CN 3-Thiophenecarboxamide, N-methyl-2-[[[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)




RN 507475-26-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-methyl-5-phenyl- (CA INDEX NAME)



RN 507475-29-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-fluorophenyl)- (CA INDEX NAME)




RN 507475-35-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-37-8 CAPLUS


CN 3-Thiophenecarboxamide, 5-(4-cyanophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-38-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-[4-(dimethylamino)phenyl]-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-39-0 CAPLUS
CN 3-Thiophenecarboxamide, 5-[4-(hydroxymethyl)phenyl]-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-40-3 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-fluorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-41-4 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-aminophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-43-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-aminophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-44-7 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-hydroxyphenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-46-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-acetylphenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-50-5 CAPLUS
CN 3-Thiophenecarboxamide, N-methyl-2-[[[(methylamino)carbonyl]amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 507475-51-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-52-7 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-aminophenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-53-8 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-hydroxy-3-methoxyphenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-54-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-(hydroxymethyl)phenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-55-0 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-56-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3-fluorophenyl)- (CA INDEX NAME)




RN 507475-57-2 CAPLUS


CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3-cyanophenyl)- (CA INDEX NAME)




RN 507475-58-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(4-ethylphenyl)- (CA INDEX NAME)




RN 507475-59-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)




RN 507475-60-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3-(hydroxymethyl)phenyl)- (CA INDEX NAME)




RN 507475-61-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 507475-62-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 507475-63-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 507475-64-1 CAPLUS
CN 3-Thiophenecarboxamide, N-(aminocarbonyl)-2-[[[(aminocarbonyl)amino]-5-phenyl)- (CA INDEX NAME)




RN 507475-65-2 CAPLUS

CN 3-Thiophenecarboxamide, N-((aminocarbonyl)-2-((methylamino)carbonyl)amino)-5-phenyl- (CA INDEX NAME)



RN 507475-67-4 CAPLUS

CN 3-Thiophenecarboxamide, N-((aminocarbonyl)-2-((methylamino)carbonyl)amino)-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 15 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STM
2003:32401 CAPLUS Full-text

DN 138:304152

TI Preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders

IN Parrish, Cynthia A.; Callahan, James F.; Wan, Zehong; Burgess, Joelle L.; Stavenger, Robert A.; Holt, Dennis A.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO	2003028731	A1	20030410	WO	2002-US31901	20021004
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RN:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO						
AU	2002330247	A1	20030414	AU	2002-330247		20021004
PRAI	US 2001-326971P	P	20011004				
WO	2002-US31901	W	20021004				
OS	MARPAT 138:304152						
GI							



AB Ureidothiophenes (shown as I; variables defined below; e.g. 5-phenyl-3-ureidothiophene-2-carboxylic acid Me ester) useful in the inhibition of angiogenesis and damage response kinases (no data) are provided. Although the methods of preparation are not claimed, 36 example preps. are included. For I: R1 = H, C1-2 alkyl, XH, XCH3, C1-2-alkyl-XH, C1-2 alkyl-XCH3, C(O)NH2, C(O)NHCH3, and C(O)-C1-2-alkyl; X = O, S, and NH; R2 = C(O)R5, CO2R5, C(O)NHR5, C(O)NHC(=NH)R5, C(O)NHC(=NH)NR5R6, C(O)NHC(O)R5, C(O)NHC(O)NR5R6, SO2R5, S(O)R5, SO3R5, and PO3R5R6. R3 is H or halogen; R4 is aryl or heteroaryl; addnl. details are given in the claims.


IT 354810-66-9P, 5-(4-Fluorophenyl)-3-ureidothiophene-2-carboxylic acid amide 354810-95-0P, 5-(4-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid amide 507472-56-2P, 5-(4-Methoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid amide 507472-64-2P, 5-(4-Methoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide 507472-66-4P, 5-(4-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid methylamide 507472-67-5P, 5-(3,4-Dimethoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide 507472-71-1P, 5-(4-Aminophenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses)

(drug candidate; preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)

RN 354810-66-9 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



2x \checkmark not in generic


RN 354810-95-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 507472-56-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(4-methoxyphenyl)-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)




RN 507472-64-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-methyl-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)




RN 507472-66-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-methyl- (CA INDEX NAME)




RN 507472-67-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)



RN 507472-71-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-(4-aminophenyl)-N-methyl-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)




IT 507472-73-2P, 5-(4-Nitrophenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)

RN 507472-73-3 CAPLUS

CN 2-Thiophenecarboxamide, N-methyl-3-[(methylamino)carbonyl]amino)-5-(4-nitrophenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:97411 CAPLUS Full-text

DN 138:137162

TI Preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase

IN Faull, Alan; Johnstone, Craig; Morley, Andrew; Poyser, Jeffrey Philip

PA AstraZeneca A.B., Swed.

SO PCT Int. Appl., 180 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003010158	A1	20030206	WO 2002-SE1403	20020719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2454703	A1	20030206	CA 2002-2454703	20020719
AU 2002355245	A1	20030217	AU 2002-355245	20020719
EP 1421074	A1	20040526	EP 2002-751935	20020719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011473	A	20041026	BR 2002-11473	20020719
CN 1541214	A	20041027	CN 2002-815836	20020719
JP 2005503372	T	20050203	JP 2003-515517	20020719
NZ 530750	A	20050826	NZ 2002-530750	20020719
US 2004242573	A1	20041202	US 2004-484569	20040122
US 7125896	B2	20061024		
ZA 2004000492	A	20050422	ZA 2004-492	20040122
NO 2004000313	A	20040325	NO 2004-313	20040123
MX 2004PA00756	A	20040420	MX 2004-PA756	20040123
HK 1071129	A1	20061229	HK 2005-103629	20050427
US 2007015819	A1	20070118	US 2006-516225	20060906
PRAI SE 2001-2616	A	20010725		
WO 2002-SE1403	W	20020719		
US 2004-484569	A3	20040122		
OS MARPAT 138:137162				
G1				



AB Title compds. I (R1 = NH2, (un)substituted methyl; X = O, S; R2 = H, halo, CN, NO2, amino, carboxamido, carboxy, etc.; A = Ph, 5-7-membered (un)substituted heteroarom. ring; n = 1-2; R3 = W-Y-Z; W = O, SOO-2; amino, CH2(O), bond; Y = (CH2)0-2-T-(CH2)0-2; T = O, CO, alkyl; Z = Ph, 5-6-membered (un)substituted heteroarom. ring, etc., with specific exceptions) are prepared. For instance, (1,1'-biphenyl-4-yl)acetone, cyanoacetamide, sulfur and morpholine in EtOH at 55° are reacted to give 2-Amino-4-methyl-5-[(1,1'-biphenyl-4-yl)-3-thiophenecarboxamide. This intermediate is treated with trichloroacetyl isocyanate and ammonia in MeOH to give example compound II. Compds. of the invention have IC50 < 10 μM for IKK2 kinase. I are useful for the treatment of inflammatory diseases.


IT 494772-63-3P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-74-6F, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]-3-thiophenecarboxamide 494772-76-8P, 2-[(Aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-59-9F, 2-[(Aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]-3-thiophenecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)


RN 494772-63-3 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (CA INDEX NAME)




RN 494772-74-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]- (CA INDEX NAME)




RN 494772-76-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (CA INDEX NAME)



RN 494773-59-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




IT 494772-73-1P, 2-[(Aminocarbonyl)amino]-5-(2-formylphenyl)-3-thiophenecarboxamide 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)


RN 494772-79-1 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-formylphenyl)- (CA INDEX NAME)



RN 494773-25-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:293385 CAPLUS Full-text

DN 136:325411

TI Preparation of 2-aminothiophene-3-carboxamides as NF-κB inhibitors

IN Callahan, James F.; Roshnak, Amy K.

PA SmithKline Beecham Corporation, USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002030353	A2	20020418	WO 2001-US31866	20011012
WO 2002030353	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002011663	A5	20020422	AU 2002-11663	20011012
EP 1324759	A2	20030709	EP 2001-979731	20011012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523476	T	20040805	JP 2002-533800	20011012
US 2004024047	A1	20040205	US 2003-378722	20030410
US 2006030596	A1	20060209	US 2005-237232	20050928

10537697 65 of 87
PRAI US 2000-239759P P 20001012
WO 2001-083186 W 20011012
US 2003-398847 B1 20030410
OS MARPAT 136:325411
GI




AB The title compds. [I; R1 = NR5R6; R2 = CONH2, SO2NH2; R3 = H, halo; R4 = aryl, heteroaryl; R5 = H, alkyl; R6 = H, Coalkyl, SO2alkyl, etc.], useful as inhibitors of IKK- β phosphorylation of I κ B, were prepared Thus, treating (4-fluorophenyl)ethanol with PCC in CH2Cl2 followed by reacting the resulting (4-fluorophenyl)acetaldehyde with sulfur and 2-cyanoacetamide in the presence of Et3N in DMF afforded 2-amino-5-(4-fluorophenyl)thiophene-3-carboxamide.


IT 106666-34-6P 106666-36-8P 412914-36-4P
412914-37-5P 412914-52-4P 412914-54-6P
412914-57-9P 412914-58-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aminothiophene-3-carboxamides as NF- κ B inhibitors)
RN 106666-34-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-phenyl]- (9CI) (CA INDEX NAME)




RN 106666-36-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




10537697 67 of 87

RN 412914-57-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-(4-methylphenyl)]- (CA INDEX NAME)



RN 412914-58-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:597977 CAPLUS Full-text
DN 135:180698

TI Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2
IN Baxter, Andrew; Brough, Stephen; Fauli, Alan; Johnstone, Craig; Mcinally, Thomas

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 85 pp.

CODEN: PIKXK2

DT Patent


LA English

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NO 2001058890	A1	20010816	WO 2001-SE248	20010207
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RN:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BR, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

10537697 66 of 87


RN 412914-36-4 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-chlorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 412914-37-5 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 412914-52-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(ethylamino)carbonyl]amino]-5-phenyl]- (CA INDEX NAME)





RN 412914-54-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(2-fluorophenyl)-2-[[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



10537697 68 of 87

CA 2396824	A1	20010816	CA 2001-2396824	20010207
EP 1261600	A1	20021204	EP 2001-902951	20010207
EP 1261600	B1	20040506		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IR, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001008143	A	20030121	BR 2001-8143	20010207
JP 2003522766	T	20030729	JP 2001-558440	20010207
AT 266019	T	20040515	AT 2001-902951	20010207
NZ 519947	A	20040528	NZ 2001-519947	20010207
PT 1261600	T	20040831	PT 2001-902951	20010207
ES 2218376	T3	20041116	ES 2001-1902951	20010207
AU 781047	B2	20050505	AU 2001-30705	20010207
US 2002107252	A1	20020808	US 2002-868884	20020205
ZA 2002005300	A	20031002	ZA 2002-5300	20020702
NO 2002003786	A	20020923	NO 2002-3786	20020809
MX 2002PA07734	A	20021011	MX 2002-PA7734	20020809
JP GB 2000-3154	A	20000212		
WO 2001-SE248	W	20010207		
OS MARPAT 135:180698				
GI				




AB The title compds. [I; A = 5-membered heteroarom. ring containing 1-2 heteroatoms selected from O, N or S; R1 = (un)substituted Ph, 5-7 membered heteroarom. ring containing 1-3 heteroatoms selected from O, N or S; R2 = H, halo, CN, etc.; X = O, S], useful in the treatment or prophylaxis of inflammatory disease, were prepared Thus, refluxing 3-amino-5-phenyl-2-thiophenecarboxamide with trimethylsilyl isocyanate in DMF/CH2Cl2 afforded II.

IT 354811-01-1P 354811-06-6P 354811-31-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-01-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)

INDEX NAME)



RN 354811-31-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)



IT 254810-80-3P 254810-83-6P 354810-86-5P

354810-88-1P 354810-90-5P 354810-95-0P

354811-04-1P 354811-07-7P 354811-08-8P

354811-09-6P 354811-10-2P 354811-14-6P

354811-15-7P 354811-19-1P 354811-27-1P

354811-28-2P 354811-29-3P 354811-30-6P

354811-32-8P 354811-33-9P 354811-34-0P

254811-35-1P 354811-36-2P 354811-37-3P

354811-38-4P 354811-39-5P 354811-40-8P

254811-41-9P 354811-42-0P 354811-48-6P

354811-49-7P 354811-50-0P 354811-52-2P

354811-54-4P 354811-56-6P 354811-58-8P

254811-59-9P 354811-60-2P 354811-66-6P

354811-67-9P 354811-68-0P 354811-82-9P


254811-81-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354810-80-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 354811-04-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)




RN 354811-07-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-08-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 354811-09-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)


RN 354810-83-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)




RN 354810-86-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




RN 354810-88-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




RN 354810-90-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(2-methylpropyl)phenyl]- (CA INDEX NAME)




RN 354810-95-0 CAPLUS




RN 354811-10-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




RN 354811-14-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)




RN 354811-15-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 354811-19-1 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)




RN 354811-27-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)




RN 354811-28-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-29-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)- (CA INDEX NAME)




RN 354811-30-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (CA INDEX NAME)




RN 354811-32-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-33-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-34-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-35-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (CA INDEX NAME)


methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-36-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-37-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-38-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-39-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-40-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-41-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 354811-42-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 354811-48-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-49-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-50-0 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-52-2 CAPLUS


RN 354811-59-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-60-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)- (CA INDEX NAME)




RN 354811-66-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-67-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (CA INDEX NAME)




RN 354811-54-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)




RN 354811-56-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (CA INDEX NAME)




RN 354811-58-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)- (CA INDEX NAME)




RN 354811-68-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 354811-82-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-83-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)




IT 354811-95-3P 354811-96-4P 354812-11-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-95-3 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-96-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354812-11-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LI0 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:423224 CAPLUS Full-text


DN 107:23224
TI Thiylureas and -isoureas and their preparation and use as growth promoters for animals
IN Hallenbach, Werner; Lindel, Hans; Berschauer, Friedrich; Scheer, Martin; De Jong, Arno
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 79 pp.
CODEN: GWXXBX

DT Patent
LA German


FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3529247	A1	19861120	DE 1985-3529247	19850816
EP 202538	A1	19861126	EP 1986-106209	19860506
EP 202538	B1	19881228		


CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-50-6 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-51-7 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(2-methylpropyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-52-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(butylamino)carbonyl]amino]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE
AT 39404 T 19890115 AT 1986-106209 19860506
AU 8657217 A 19861120 AU 1986-57217 19860507
JP 6126678 A 19861128 JP 1986-109713 19860515
DK 8602300 A 19861118 DK 1986-2300 19860516
BR 8602224 A 19870113 BR 1986-2224 19860516
ZA 8603645 A 19870128 ZA 1986-3645 19860516
HU 41244 A2 19870428 HU 1986-2086 19860516
ES 555052 A1 19880216 ES 1986-555052 19860516
CS 258481 B2 19880816 CS 1986-3569 19860516
FI 8602201 A 19861118 FI 1986-2201 19860526
PRAI DE 1985-3517706 A1 19850517
DE 1985-3529247 A 19850816
EP 1986-106209 A 19860506
OS CASREACT 107:23224
GI




AB Title compds. I (A = NR4CONR5R6, NR4C(OR5)NR6; R1, R2 = H, halo, NO2, CN, (halo)alkoxy, (halo)alkylthio, alkoxyalkyl, (un)substituted acyl, aryl, alkyl, aryl; R1R2 complete a(n) (un)substituted carbocyclic or heterocyclic ring, optionally with a carbonyl function; R3 = CN, CO2R7, CONR8R9, COR10; R4 = H, alkyl; R5, R6 = H, (un)substituted alkyl, cycloalkyl, alkenyl, aryl, heteroaryl; R7 = H, (un)substituted alkyl, cycloalkyl, alkenyl, aryl; R8 = H, alkyl, cycloalkyl; R9, R10 = (un)substituted alkyl or aryl), useful as growth promoters for animals, were prepared by 3 methods. 2-Aminotetrahydrobenzothiothiophene-3-carboxamide and MeNCO in CHCl3 were refluxed 24 h to give 95% II. Rats fed with 10 ppm II mixed in their feed gained 14% more weight than the controls.

IT 106666-34-6P 106666-36-8P 106666-50-6P
106666-51-7P 106666-52-8P 106666-20-9P
108354-55-8P 108354-56-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as animal growth promoter)

RN 106666-34-6 CAPLUS


CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-36-8 CAPLUS


RN 106666-20-8 CAPLUS

CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 108354-55-8 CAPLUS

CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylpropyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 108354-56-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



(LI0 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN)

AN 1987:83475 CAPLUS Full-text

DN 106:83475

TI Productivity-increasing agents for livestock

IN Hallenbach, Werner; Lindel, Hans; Berschauer, Friedrich; Scheer, Martin;

De Jong, Arno

PA Bayer A.-G., Fed. Rep. Ger.

SO Eur. Pat. Appl., 80 pp.

CODEN: EPXXDM

DT Patent

LA German

FAN.CNT 2

10537697

85 of 87


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 202538	A1	19861126	EP 1986-106209	19860506
EP 202538	B1	19861228		
RI, AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
DE 3529247	A1	19861120	DE 1985-3529247	19850816
AT 39404	T	19890115	AT 1986-106209	19860506
PRA1 DE 1985-3517706	A	19850517		
DE 1985-3529247	A	19850816		
EP 1986-106209	A	19860506		
OS MARPAT 106:83475				
GI				



AB Productivity-increasing agents for livestock comprise thienylurea or thienylisourea derivs. I (A = NH₂, NCO, NR₄CONR₅R₆, NHR₄, NR₄C(OR₅)NR₆; R₁, R₂ = H, halogen, nitro, CN, (un)substituted alkyl, aryl, etc.; R₃ = CN, COOR₇, CONR₈R₉, COR₁₀; R₄ = H, alkyl; R₅, R₆ = H, substituted alkyl, cycloalkyl, alkenyl, aryl, heteroaryl; R₇ = H, substituted alkyl, cycloalkyl, alkenyl, aryl; R₈ = H, alkyl, cycloalkyl; R₉ = H, substituted alkyl or aryl; R₁₀ = substituted alkyl or aryl). Thus, 218 thienylurea and thienylisourea compds. were prepared. N-Butyl-N'-(3-methoxycarbonyltetrahydrobenzothien-2-yl)urea, given to rats at 25 ppm. in their feed for 13 days increased weight gain by 13% over that of control rats.

IT 106666-34-6P 106666-36-8P 106666-50-6P
106666-51-7P 106666-52-3P 106666-20-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as livestock productivity-increasing agent)


RN 106666-34-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-phenyl]- (9CI) (CA INDEX NAME)




RN 106666-36-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)

10537697


86 of 87




RN 106666-50-6 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(methylamino)carbonyl]amino]-5-phenyl]- (9CI) (CA INDEX NAME)



RN 106666-51-7 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(2-methylpropyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-52-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(butylamino)carbonyl]amino]-4-methyl-5-phenyl]- (9CI) (CA INDEX NAME)



RN 106666-20-8 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)

10537697

87 of 87



** d cost

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
CONNECT CHARGES	0.41	2.92
NETWORK CHARGES	0.06	0.48
SEARCH CHARGES	0.00	180.62
DISPLAY CHARGES	108.23	108.23
FULL ESTIMATED COST	108.70	292.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.38	-16.38

IN FILE 'CAPLUS' AT 11:01:25 ON 20 NOV 2007

** log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	108.70	292.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.38	-16.38

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:01:31 ON 20 NOV 2007